Literature DB >> 18397472

G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells.

Akira Ichikawa1, Jiro Ando, Koichi Suda.   

Abstract

Treatment of exponentially growing MCF-7 human breast carcinoma cells with tamoxifen (TAM) inhibits cell growth in a dose-dependent manner. However, the molecular basis for the drug's activity and its relationship to the cell cycle have not yet been clearly established. In this study, we analyzed cell cycle-related proteins used for immunoblotting and flow cytometry in TAM-treated MCF-7 cells. In addition, the ratio of apoptosis in the cell was analyzed using labeling of DNA strand breaks (TdT assay). In flow-cytometric DNA distribution analysis, the S-phase fraction showed a marked decrease and a concomitant increase in G1- and G2-phase cells accompanying the inhibitory effect of TAM; these changes were time- and dose-dependent. Immunoblotting revealed that the levels of p53 and p21(WAF1/CIP1) in TAM-treated cells increased in a time- and dose-dependent manner, whereas those of p27(KIP1) and p16 slightly increased or remained unchanged. Furthermore, cyclin D3 and B showed sharp decreases, in contrast with p53 and p21(WAF1/CIP1) DNA-apoptosis dual analysis using flow cytometry revealed that the TAM-treated samples contained apoptotic cells, the majority of which were arrested in G1 or G2 and showed suppression of Bcl-2 protein. These results suggest that the tumorigenic effect of TAM on MCF-7 cells arises through antitumor effects that are due to the expression of cyclin-dependent kinase inhibitors, especially p21(WAF1/CIP1) and these are regulated by the decrease of wild-type p53. The proposed mechanism is similar to that underlying the cytotoxic effects of other agents and ionizing irradiation that cause DNA damage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397472     DOI: 10.1111/j.1749-0774.2008.00048.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  44 in total

1.  Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen.

Authors:  P E Budtz
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

2.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

3.  The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.

Authors:  Isabel Chu; Kimberly Blackwell; Susie Chen; Joyce Slingerland
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

4.  Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells.

Authors:  K Smolnikar; S Löffek; T Schulz; H Michna; P Diel
Journal:  Breast Cancer Res Treat       Date:  2000-10       Impact factor: 4.872

5.  Estrogen stimulates transcription of c-jun protooncogene.

Authors:  A Weisz; L Cicatiello; E Persico; M Scalona; F Bresciani
Journal:  Mol Endocrinol       Date:  1990-07

6.  Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation.

Authors:  Y Xiong; H Zhang; D Beach
Journal:  Genes Dev       Date:  1993-08       Impact factor: 11.361

7.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle.

Authors:  R L Sutherland; M D Green; R E Hall; R R Reddel; I W Taylor
Journal:  Eur J Cancer Clin Oncol       Date:  1983-05

9.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.

Authors:  M H Lee; I Reynisdóttir; J Massagué
Journal:  Genes Dev       Date:  1995-03-15       Impact factor: 11.361

10.  Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time.

Authors:  Ida R K Bukholm; Anne Husdal; Jahn M Nesland; Anita Langerød; Geir Bukholm
Journal:  Breast Cancer Res Treat       Date:  2003-07       Impact factor: 4.872

View more
  9 in total

Review 1.  Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.

Authors:  Carol A Lange; Douglas Yee
Journal:  Endocr Relat Cancer       Date:  2011-07-04       Impact factor: 5.678

Review 2.  Minireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer.

Authors:  Stéphanie Légaré; Mark Basik
Journal:  Mol Endocrinol       Date:  2016-07-20

3.  Regulation of hormonal therapy resistance by cell cycle machinery.

Authors:  Binoj Chandrasekharan Nair; Ratna K Vadlamudi
Journal:  Gene Ther Mol Biol       Date:  2008-01-01

Review 4.  Progress with palbociclib in breast cancer: latest evidence and clinical considerations.

Authors:  Andrea Rocca; Alessio Schirone; Roberta Maltoni; Sara Bravaccini; Lorenzo Cecconetto; Alberto Farolfi; Giuseppe Bronte; Daniele Andreis
Journal:  Ther Adv Med Oncol       Date:  2016-11-21       Impact factor: 8.168

5.  Reinforcing targeted therapeutics with phenotypic stability factors.

Authors:  Paul Yaswen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  Anti-apoptotic effect of claudin-1 in tamoxifen-treated human breast cancer MCF-7 cells.

Authors:  Harue Akasaka; Fuyuki Sato; Satoko Morohashi; Yunyan Wu; Yang Liu; Jun Kondo; Hiroki Odagiri; Kenichi Hakamada; Hiroshi Kijima
Journal:  BMC Cancer       Date:  2010-10-12       Impact factor: 4.430

7.  Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.

Authors:  Samy A F Morad; Jonathan C Levin; Sriram S Shanmugavelandy; Mark Kester; Gemma Fabrias; Carmen Bedia; Myles C Cabot
Journal:  Mol Cancer Ther       Date:  2012-09-07       Impact factor: 6.261

Review 8.  The p53-estrogen receptor loop in cancer.

Authors:  C Berger; Y Qian; X Chen
Journal:  Curr Mol Med       Date:  2013-09       Impact factor: 2.222

9.  An aqueous extract of Fagonia cretica induces DNA damage, cell cycle arrest and apoptosis in breast cancer cells via FOXO3a and p53 expression.

Authors:  Matt Lam; Amtul R Carmichael; Helen R Griffiths
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.